Theragnostic liposomes for the diagnosis and treatment of tuberculosis

Jiménez-Rodríguez, Rebeca; Douda, J.; Mota-Díaz, Isaac I.; Luna-Herrera, Julieta; Romera-Ibarra, I. C.; Casas-Espínola, J. L.

doi:10.1557/s43580-023-00496-3

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Jiménez-Rodríguez et al successfully encapsulated RIF in liposomes and silver nanoparticles to develop a luminescent biomarker for its evaluation as a TB theranostic. The particles permitted early diagnosis and treatment, and, due to their optical properties, the authors highlighted their utility in pharmacokinetic studies [ 124 ].…”

Section: Particulate Systems For the Administration Of Vaccines And T...mentioning

confidence: 99%

The Use of Particulate Systems for Tuberculosis Prophylaxis and Treatment: Opportunities and Challenges

et al. 2023

View full text Add to dashboard Cite

The use of particles to develop vaccines and treatments for a wide variety of diseases has increased, and their success has been demonstrated in preclinical investigations. Accurately targeting cells and minimizing doses and adverse side effects, while inducing an adequate biological response, are important advantages that particulate systems offer. The most used particulate systems are liposomes and their derivatives, immunostimulatory complexes, virus-like particles, and organic or inorganic nano- and microparticles. Most of these systems have been proven using therapeutic or prophylactic approaches to control tuberculosis, one of the most important infectious diseases worldwide. This article reviews the progress and current state of the use of particles for the administration of TB vaccines and treatments in vitro and in vivo, with a special emphasis on polymeric particles. In addition, we discuss the challenges and benefits of using these particulate systems to provide researchers with an overview of the most promising strategies in current preclinical trials, offering a perspective on their progress to clinical trials.

show abstract

Section: Particulate Systems For the Administration Of Vaccines And T...mentioning

confidence: 99%